These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23091058)

  • 41. Fenofibrate unexpectedly induces cardiac hypertrophy in mice lacking MuRF1.
    Parry TL; Desai G; Schisler JC; Li L; Quintana MT; Stanley N; Lockyer P; Patterson C; Willis MS
    Cardiovasc Pathol; 2016; 25(2):127-140. PubMed ID: 26764147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypertrophy, gene expression, and beating of neonatal cardiac myocytes are affected by microdomain heterogeneity in 3D.
    Curtis MW; Sharma S; Desai TA; Russell B
    Biomed Microdevices; 2010 Dec; 12(6):1073-85. PubMed ID: 20668947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
    Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
    Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy.
    Yang J; Nie Y; Wang F; Hou J; Cong X; Hu S; Chen X
    Biochim Biophys Acta; 2013 Aug; 1831(8):1386-94. PubMed ID: 23711961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Nogo-B promotes cardiac hypertrophy via endoplasmic reticulum stress.
    Li J; Wu W; Xin Y; Zhao M; Liu X
    Biomed Pharmacother; 2018 Aug; 104():193-203. PubMed ID: 29772440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways.
    Li HL; Wang AB; Huang Y; Liu DP; Wei C; Williams GM; Zhang CN; Liu G; Liu YQ; Hao DL; Hui RT; Lin M; Liang CC
    Free Radic Biol Med; 2005 Jan; 38(2):243-57. PubMed ID: 15607907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-297 promotes cardiomyocyte hypertrophy via targeting sigma-1 receptor.
    Bao Q; Zhao M; Chen L; Wang Y; Wu S; Wu W; Liu X
    Life Sci; 2017 Apr; 175():1-10. PubMed ID: 28286226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calcineurin Aβ-Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy.
    Li X; Li J; Martinez EC; Froese A; Passariello CL; Henshaw K; Rusconi F; Li Y; Yu Q; Thakur H; Nikolaev VO; Kapiloff MS
    Circulation; 2020 Sep; 142(10):948-962. PubMed ID: 32611257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
    Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myocyte adrenoceptor signaling pathways.
    Xiang Y; Kobilka BK
    Science; 2003 Jun; 300(5625):1530-2. PubMed ID: 12791980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phospholipase C epsilon scaffolds to muscle-specific A kinase anchoring protein (mAKAPbeta) and integrates multiple hypertrophic stimuli in cardiac myocytes.
    Zhang L; Malik S; Kelley GG; Kapiloff MS; Smrcka AV
    J Biol Chem; 2011 Jul; 286(26):23012-21. PubMed ID: 21550986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Propofol ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction via heme oxygenase-1/signal transducer and activator of transcription 3 signaling pathway in rats.
    Xu J; Li H; Irwin MG; Xia ZY; Mao X; Lei S; Wong GT; Hung V; Cheung CW; Fang X; Clanachan AS; Xia Z
    Crit Care Med; 2014 Aug; 42(8):e583-94. PubMed ID: 24810525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling.
    Horikawa YT; Panneerselvam M; Kawaraguchi Y; Tsutsumi YM; Ali SS; Balijepalli RC; Murray F; Head BP; Niesman IR; Rieg T; Vallon V; Insel PA; Patel HH; Roth DM
    J Am Coll Cardiol; 2011 May; 57(22):2273-83. PubMed ID: 21616289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estrogen receptor beta maintains expression of KLF15 to prevent cardiac myocyte hypertrophy in female rodents.
    Hoa N; Ge L; Korach KS; Levin ER
    Mol Cell Endocrinol; 2018 Jul; 470():240-250. PubMed ID: 29127073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
    Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
    J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systems biology approach identifies key regulators and the interplay between miRNAs and transcription factors for pathological cardiac hypertrophy.
    Recamonde-Mendoza M; Werhli AV; Biolo A
    Gene; 2019 May; 698():157-169. PubMed ID: 30844478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
    Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
    Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of cardiac hypertrophy by aromadendrin through down-regulating NFAT and MAPKs pathways.
    Cui S; Cui Y; Li Y; Zhang Y; Wang H; Qin W; Chen X; Ding S; Wu D; Guo H
    Biochem Biophys Res Commun; 2018 Dec; 506(4):805-811. PubMed ID: 30389139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular targets and regulators of cardiac hypertrophy.
    Rohini A; Agrawal N; Koyani CN; Singh R
    Pharmacol Res; 2010 Apr; 61(4):269-80. PubMed ID: 19969085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation.
    Tanner MA; Thomas TP; Grisanti LA
    J Mol Cell Cardiol; 2019 Nov; 136():1-14. PubMed ID: 31473246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.